After JAK Inhibitor Failure: To Cycle Or To Switch, That Is The Question – Data From The JAK-Pot Collaboration of Registries
Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835
Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Blocking the IL-6R is a major therapeutic advance for many diseases in adults and children. Updated consensus statement provides guidance to rheumatologists and other experts, as well as patients and administrators, on managing patients with the use of drugs blocking the IL-6 pathway.
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586
Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.